Static Chart BioInvent International AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 11:29:45 2024-05-24 EDT			5-day change	1st Jan Change
32.95 ^SEK	+3.62%		+10.02%	+73.79%

05-23	BioInvent Presents Promising Phase 1 Data for Bi-1206 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Solid Tumors	CI
05-23	BioInvent International AB Presents Promising Clinical Efficacy and Safety for Anti-Tnfr2 Agent BI-1808 At Asco 2024	CI

Duration

Period